- Home
- OXBR vs APRE Comparison
OXBR vs APRE Comparison
Compare OXBR & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXBR
- APRE
- Stock Information
- Founded
- OXBR 2013
- APRE 2006
- Country
- OXBR Cayman Islands
- APRE United States
- Employees
- OXBR N/A
- APRE 8
- Industry
- OXBR Property-Casualty Insurers
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OXBR Finance
- APRE Health Care
- Exchange
- OXBR Nasdaq
- APRE Nasdaq
- Market Cap
- OXBR 11.3M
- APRE 8.4M
- IPO Year
- OXBR 2014
- APRE 2019
- Fundamental
- Price
- OXBR $1.39
- APRE $1.60
- Analyst Decision
- OXBR
- APRE Strong Buy
- Analyst Count
- OXBR 0
- APRE 2
- Target Price
- OXBR N/A
- APRE $15.50
- AVG Volume (30 Days)
- OXBR 25.9K
- APRE 29.2K
- Earning Date
- OXBR 05-08-2025
- APRE 05-13-2025
- Dividend Yield
- OXBR N/A
- APRE N/A
- EPS Growth
- OXBR N/A
- APRE N/A
- EPS
- OXBR N/A
- APRE N/A
- Revenue
- OXBR $546,000.00
- APRE $1,502,581.00
- Revenue This Year
- OXBR N/A
- APRE N/A
- Revenue Next Year
- OXBR N/A
- APRE N/A
- P/E Ratio
- OXBR N/A
- APRE N/A
- Revenue Growth
- OXBR N/A
- APRE 157.63
- 52 Week Low
- OXBR $1.01
- APRE $1.41
- 52 Week High
- OXBR $5.81
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- OXBR 22.94
- APRE 31.36
- Support Level
- OXBR $1.42
- APRE $1.41
- Resistance Level
- OXBR $1.56
- APRE $1.59
- Average True Range (ATR)
- OXBR 0.16
- APRE 0.10
- MACD
- OXBR 0.05
- APRE 0.03
- Stochastic Oscillator
- OXBR 7.48
- APRE 31.26
About OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.